Potential therapeutic strategies for MASH: from preclinical to clinical development  

作　　者：Zhifu Xie Yufeng Li Long Cheng Yidan Huang Wanglin Rao Honglu Shi Jingya Li 

机构地区：[1]State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China [2]University of Chinese Academy of Sciences,Beijing 100049,China [3]School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,University of Chinese Academy of Sciences,Hangzhou,Zhejiang 310024,China

出　　处：《Life Metabolism》2024年第5期45-60,共16页生命代谢（英文）

基　　金：supported by grants from the National Natural Science Foundation of China(92057116 to J.L.;82170872 to Z.X.,and 82200965 to Y.L.);the Natural Science Foundation of Shanghai’s 2021“Science and Technology Innovation Action Plan”(21ZR1475300 to Z.X.);Shanghai Science and Technology Development Funds(22YF1456900 to Y.L.).

摘　　要：Current treatment paradigms for metabolic dysfunction-associated steatohepatitis(MASH)are based primarily on dietary restrictions and the use of existing drugs,including anti-diabetic and anti-obesity medications.Given the limited number of approved drugs specifically for MASH,recent efforts have focused on promising strategies that specifically target hepatic lipid metabolism,inflamma-tion,fibrosis,or a combination of these processes.In this review,we examined the pathophysiology underlying the development of MASH in relation to recent advances in effective MASH therapy.Particularly,we analyzed the effects of lipogenesis inhibitors,nuclear receptor agonists,glucagon-like peptide-1(GLP-1)receptor(GLP-1R)agonists,fibroblast growth factor mimetics,and combinatorial therapeutic approaches.We summarize these targets along with their preclinical and clinical candidates with the ultimate goal of optimizing the therapeutic prospects for MASH.

关 键 词：STEATOSIS inflammation FIBROSIS metabolic dysfunction-associated steatohepatitis PHARMACOTHERAPY 

分 类 号：R575.1[医药卫生—消化系统]